European guideline for coeliac disease

Overview

Al-Toma A et al.. United European Gastroenterol J 2019 · PMID 31210940 · DOI 10.1177/2050640619844125

Coeliac disease needs a strict lifelong gluten-free diet; gluten is in wheat, rye and barley (not in uncontaminated rice, maize or oats); non-coeliac gluten sensitivity is recognised after coeliac disease and wheat allergy are excluded.

Does the study support the specific claim? No · Methodological quality: moderate

Original publication

Plain-language summary

Scientific in-depth review

1. Full reference

Authors

Al-Toma A et al.

Journal

United European Gastroenterol J

Year

2019

Identifier

PMID 31210940 DOI 10.1177/2050640619844125

Verification

verified – PubMed efetch 2026-10-25

Retracted

no

Corrections

none

Extent checked

full text

Conflicts of interest and funding

No funding or conflict-of-interest statement found in the full-text PDF available (Amsterdam UMC repository version).

2. Research question

Diagnosis and management of coeliac disease and gluten-related disorders

3. Study design and population

Study design

Guideline / position statement – Clinical practice guideline (expert consensus of the ESsCD board, incl. 2 ESPGHAN-nominated paediatric representatives) based on a PubMed literature review, with GRADE grading of recommendations

Population

Adults and children with coeliac disease (CD), dermatitis herpetiformis, non-coeliac gluten sensitivity (NCGS), gluten ataxia and other gluten-related disorders

Country

Europe (authors from the Netherlands, Italy, Spain, UK, France, Norway)

Period

Literature search PubMed 1 January 1990 to 2018 (search and first draft January-August 2018; consensus meeting Vienna, October 2018); published June 2019

Sample size

not applicable

Inclusion and exclusion criteria

PubMed search for 'celiac', 'coeliac', 'non-tropical sprue', 'gluten', 'dermatitis herpetiformis', 'enteropathy', 'ataxia', no language restriction; emphasis on publications since 2000 plus older landmark papers; mainly cohort and case-control studies, few RCTs and selected non-controlled studies. No systematic review protocol or explicit selection criteria reported.

4. Methods and endpoints

Exposure / intervention

Not applicable

Comparator

Not applicable

Endpoints

Recommendations on diagnosis, dietary management, follow-up, complications, NCGS, skin and neurological manifestations

Statistical methods

Not applicable; GRADE (strong/conditional recommendation; high/moderate/low evidence quality); consensus by board review and meeting

5. Actual results

Results

Key recommendations: CD patients should adhere to a lifelong gluten-free diet (strong, high evidence); gluten and gluten-related proteins are present in wheat, rye and barley, while maize and oats are normally gluten-free but may be contaminated; uncontaminated oats are tolerated by most CD patients, introduce cautiously (strong, moderate); EU law (EC 41/2009) defines 'gluten-free' as <=20 ppm, regarded safe for CD; daily gluten <10 mg unlikely to cause significant histological damage; advise high-fibre diet with whole-grain rice, maize, potatoes and vegetables (strong, moderate); testing must be done on a gluten-containing diet; malabsorption in CD results from immune-mediated small-bowel mucosal damage with loss of absorptive surface. NCGS: IBS-like and extra-intestinal symptoms after gluten, improving on withdrawal and relapsing on challenge, after exclusion of CD and wheat allergy; may be considered in such patients (strong, moderate); excluded if no improvement after 6 weeks of GFD (strong, moderate); a less stringent GFD may suffice (conditional, low); no specific biomarkers; ATIs and fructans (FODMAPs) are possible alternative culprits. CD prevalence in Western countries about 0.6% (biopsy-confirmed) and 1% (serological screening).

Absolute risks

not applicable

Authors' conclusion

Treatment of CD is primarily a lifelong gluten-free diet requiring education and dietitian follow-up; persistent symptoms require diagnostic review and exclusion of complications; NCGS and gluten-related neurological manifestations are recognised but less well defined and need biomarkers and further research.

6. Strengths

• Multinational, multidisciplinary European society guideline covering adults and children
• Explicit GRADE strength and evidence-quality labels for each recommendation
• Clear operational criteria for CD diagnosis and a stepwise NCGS diagnostic approach
• States areas of uncertainty and research needs

7. Weaknesses

• Literature search in PubMed only; no systematic review, evidence tables or explicit study selection criteria
• Consensus by a small board (8 authors); no patient, dietitian or methodologist involvement reported
• No funding or COI declaration in the available full text (editorial independence not verifiable)
• GRADE judgements not accompanied by evidence profiles
• NCGS recommendations rest on moderate-to-low evidence and lack biomarkers

8. Risk of bias

Orienting tool

No standard tool fits exactly (guideline); structured judgement oriented on AGREE II domains

Type of assessment

structured assessment based on the full text by a single reviewer (no formal double review)

Full formal assessment

no

Overall risk of bias

some concerns

Rationale

Changed from not_assessable to some_concerns after full-text review. Core recommendations relevant here (lifelong GFD in CD; gluten in wheat/rye/barley, not in uncontaminated maize, oats, rice; NCGS as an entity after exclusion of CD/WA) are consistent with other international guidelines, so the methodological concerns do not undermine them. Simplified single-reviewer judgement; a formal AGREE II appraisal needs at least two independent appraisers.

Full-text review (25 October 2026): Extracted specific recommendations with GRADE levels (lifelong GFD strong/high; oats; <=20 ppm EU labelling; whole-grain rice/maize advised; NCGS diagnostic and management recommendations), definition of gluten-containing cereals, mechanism of CD malabsorption, guideline methods (PubMed-only, consensus). Bias changed from not_assessable to some_concerns (AGREE II-oriented); methodological quality lowered from high to moderate; no COI/funding statement found.

9. Assessment of the statistical interpretation

Not applicable; recommendations graded by GRADE. The lifelong GFD recommendation carries high-quality evidence; NCGS management recommendations are conditional with low evidence.

10. Relevance to the specific claim

Medical standard against C-GRN-01/02/03 and C-WHT-02.

11. Independent contrary findings

12. Transferability to Germany and Europe

Directly applicable in EU.

13. Overall methodological judgement

Authoritative European consensus guideline with moderate methodological rigour. Directly contradicts claims that gluten is present in all grains, that gluten sensitivity does not exist, or that people with CD can reintroduce gluten-containing bread.

14. Open questions

Biomarkers and prevalence of NCGS; relative roles of gluten vs fructans/ATIs in NCGS symptoms.

15. Linked fact checks

• 'There is no such thing as gluten sensitivity'; the real problem is only that white flour turns into a glue-like substance. – Studies contradicting or limiting the claim
• Gluten is present in all grains, including oats, rice and maize, so 'gluten-free' bread or flour is a meaningless concept. – Studies contradicting or limiting the claim
• In a joint live stream on Elawady's channel, a speaker (Elawady or his guest Dr. Tamer El-Baz; speaker turns cannot be identified) describes a coeliac patient on the system who reintroduced gluten-containing toast, and advises pausing it when symptoms appear and reintroducing it later. – Studies contradicting or limiting the claim
• White flour coats the absorptive villi of the small intestine like glue and thereby causes malabsorption, which leads to irritable bowel syndrome, iron-deficiency anaemia, vitamin D deficiency, weak bones and teeth, fatty liver and hair loss. – Studies contradicting or limiting the claim